Cancer

The agreement covers joint clinical studies that will combine BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors developed by Revolution Medicines: daraxonrasib, zoldonrasib, elironrasib and RMC-5127.

The decision follows the failure of the phase 3 Lagoon trial, which did not meet its primary endpoint of overall survival.

eyonis LCS is a Software as a Medical Device that uses AI to assist clinicians in detecting and diagnosing lung cancer during screening workflows.

The US Food and Drug Administration (FDA) approved Jideytro for adults with locally advanced or metastatic ROS1-positive NSCLC who have previously received treatment with a ROS1 kinase inhibitor.

Breast cancer remains the country’s most commonly diagnosed cancer, accounting for 5,822 new cases, or 16.2% of all cancers.

Researchers will use GE HealthCare’s StarGuide SPECT/CT imaging system together with MIM Software’s MIM LesionID Pro platform to monitor how tumours respond throughout treatment.

Unlike conventional open surgery, which requires large incisions in the chest and abdomen, MIE uses several small incisions, high-definition imaging, and specialized laparoscopic instruments.

The initiative will support patients with the greatest medical and financial needs by improving access to advanced therapies within a framework aligned with the UAE’s national health insurance system.

Astex will also qualify for development, regulatory, and commercial milestone payments exceeding US$465 million, totaling US$490 million with the upfront payment included.

Founded in 2019 as a spinout from Imperial College London and the Francis Crick Institute, Myricx has attracted strong investor backing and has emerged as one of the UK’s leading oncology biotechnology companies.